Join
Live feed
·
PRReleasevia Quantisnow
PDS Biotechnology Corporation logo

PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022

ByQuantisnow·Wall Street's wire, on your screen.
PDSB· PDS Biotechnology Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PDSB (PDS Biotechnology Corporation) and more on Quantisnow.